Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The immunosuppressive strategies devised by neuroblastoma (NB), the most common solid extracranial childhood cancer, are poorly understood. Here, we identified an immunoevasive program triggered by NB through secretion of galectin‐1 (Gal‐1), a multifunctional glycan‐binding protein. Human and mouse NB cells express and secrete Gal‐1, which negatively regulates T cell and dendritic cell function. When injected subcutaneously in syngeneic A/J mice, knockdown transfectants expressing low amounts of Gal‐1 (NXS2/L) showed reduction of primary tumor growth by 83–90% and prevented spontaneous liver metastases in contrast to NXS2 cell variants (NXS2/H, NXS2 wildtype) expressing high amounts of Gal‐1. Splenocytes from mice receiving Gal‐1 knockdown NXS2/L cells secreted higher amounts of IFN‐γ and displayed enhanced cytotoxic T‐cell function compared to NXS2/H or NXS2 controls. Immunohistochemical analysis revealed a six‐ to tenfold increase in the frequency of CD4+ and CD8+ T cells infiltrating tumors from mice receiving knockdown transfectants. This effect was confirmed by in vitro migration assays. Finally, supernatants of NXS2/H or NXS2 cells suppressed dendritic cell (DC) maturation and induce T cell apoptosis, whereas these effects were only marginal on DCs and T cells exposed to supernatants from NXS2/L cells. These results demonstrate a novel immunoinhibitory role of the Gal‐1‐glycan axis in NB, highlighting an alternative target for novel immunotherapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 1×
“Treatment with IL-2, GM-CSF, CD40 agonists or CTLA-4 blockade, in combination with other traditional approaches, has successfully improved immune effector functions in high-risk NB patient.(5,6) However, the success of these adjuvant immunotherapeutic approaches is hindered by a number of strategies used by tumors or…”
BackgroundToscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., Hernandez, J. D., Zwirner, N. W., Poirier, F., Riley, E. M., Baum, L. G., et al. (2007) · Nature Immunology · doi:10.1038/ni1482 · Cited by 653
Self-citation
Cited by
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
“Gabriel Rabinovich (Instituto de Biologica y Medicina Experimental, Buenos Aires, Argentina) discussed how galectin-1 associated with VEGFR2 in tumor-associated endothelial cell stimulated VEGFR2mediated signaling and angiogenesis in the absence of VEGF (14).”
InfluentialGlycobiology of immune responses
Rabinovich, G. A., van Kooyk, Y., & Cobb, B. A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06492.x · Cited by 279
Self-citationDalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Méndez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2418 · Cited by 261
Self-citation
Metadata
- Authors
- Soldati, R., Berger, E., Zenclussen, A. C., Jorch, G., Lode, H. N., Salatino, M., Rabinovich, G. A., & Fest, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-12-05
- Volume
- 131
- Issue
- 5
- Pages
- 1131-1141
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2052253338
- Cited by
- 79
- References
- 2
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments. https://app.cochat.ai/papers/10.1002/ijc.26498
- The paper
- Soldati, R., Berger, E., Zenclussen, A. C., Jorch, G., Lode, H. N., Salatino, M., Rabinovich, G. A., & Fest, S. (2012). Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments. International Journal of Cancer. https://doi.org/10.1002/ijc.26498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.